Fifty Years — 2024 Investments
3 investments dated 2024 · listed companies and verified rows first · show all
Kano Therapeutics develops circular single-stranded DNA (cssDNA) as a genetic payload for gene-editing and other DNA-based therapies, offering an alternative to viral vectors and double-stranded DNA.
BiotechDeep TechCambridge, US
Floris Engelhardt(Executive Officer, Director)John Vroom(Director)
BoardAnn DeWitt(Director)in
Co-investorsLaunchpad Venture GroupMetaplanetThe Engine VenturesVsquared VenturesZAKA VC
ResistanceBio develops treatments to address drug resistance in cancer patients.
BiotechHealthtechSan Francisco, US
Nicholas Goldner(CEO/Founder)inChristopher Bulow(Founder)inKYLE LAPHAM(Executive Officer, Director)
BoardOMRI AMIRAV-DRORY(Director)in
Co-investorsY CombinatorNFX
Talus develops a proprietary platform that measures and modulates the regulome—the body's gene expression control system—in native cellular contexts.
AI & Machine LearningBiotechDeep TechHealthtechSeattle, US
Alex Federation(Founder)inLindsay Pino(Founder)in
BoardOmri Amirav-Drory(Director)inJ. Seth Strattan(Director)in
Co-investorsFarvatn VentureFundersClubNFXTwo Bear CapitalY CombinatorBoxOne Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.